Drug Repurposing News



Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS): Mar 2017

March 16th 2017, Posted by: Drug Repurposing Portal

The DPFS scheme is a key part of our Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including ?repurposing? of existing therapies. The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.


News Methods Funding Collaborations

NCATS Seeks Applications to Repurpose Existing Drugs

February 15th 2017, Posted by: Drug Repurposing Portal

In collaboration with AstraZeneca and Janssen Research & Development, LLC, NCATS is seeking applications through its NIH-Industry Partnerships initiative to explore new treatments for patients, using existing experimental drugs or biologics. NCATS plans to commit an estimated $6 million to fund six to 10 awards to support partnerships between the pharmaceutical companies and the biomedical research community by making a selection of industry assets available to test ideas for new therapeutic uses.


News Methods Funding Collaborations

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

February 8th 2017, Posted by: Drug Repurposing Portal

Atriva Therapeutics was founded in T?bingen, Germany in 2015 with a quite particular aim: repurposing cancer drugs to treat influenza. Two private investors, the Dutch Stichting Participatie Atriva and the German High-Tech Gr?nderfonds (HTGF) have contributed with an undisclosed amount of seed funding that will help the young biotech push its first drug candidate to the clinic. Atriva?s lead candidate, ATR-002, is expected to enter clinical trials in 2018. The drug is intended for treating influenza in high-risk patients with severe respiratory complications due to bacterial co-infections


News Methods Funding Collaborations

Ocugen Closes $6 Million in Series A Funding

December 15th 2016, Posted by: Drug Repurposing Portal

Ocugen, Inc., a biopharmaceutical company developing treatments for sight-threatening diseases, today announced that it has closed a $6 million round of Series A funding to continue development efforts for its lead asset "OCU300", a repurposed drug with an established safety track record in ocular applications that is being developed for the treatment of ocular graft versus host disease (oGVHD) under the U.S. Food and Drug Agency's 505(b)(2) regulatory pathway.


News Methods Funding Collaborations

Healx secures ?1.5m from Amadeus Capital and investors to combat rare diseases

October 4th 2016, Posted by: Drug Repurposing Portal

Amadeus Capital Partners, the global technology investor, has made an early-stage investment in Healx, an innovative British healthcare company that seeks new uses for existing drugs in the fight against rare diseases. Amadeus Capital is investing in a ?1.5 million Series A round, alongside renowned healthcare entrepreneur, Jonathan Milner. Healx, founded and based in Cambridge, operates in the fast-growing drug ?repurposing? sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide.


News Methods Funding Collaborations

Well-connected IT-enabled drug repurposing shop raises cash for rare disease R&D push

October 4th 2016, Posted by: Drug Repurposing Portal

Healx, a British startup have got notable investments to repurpose drugs for rare diseases. Healx will step up the expansion of literature mining methods to suggest new uses of old drugs. The company is little different from the fellow drug repurposing shops, both in terms of how it is applying its technology and who it has persuaded to play a role in its advance.


News Methods Funding Collaborations

Bench-to-Clinic Repurposing Initiative

August 25th 2016, Posted by: Drug Repurposing Portal

Recently, NCATS announced a funding opportunity to explore a potential new use of an existing investigational, Phase IIa-ready, Food and Drug Administration-approved drug, or licensed biologic. Through the Bench-to-Clinic Repurposing initiative, NCATS will support pre-clinical studies to demonstrate the usefulness of drug-indication pairing method emerged from independent crowdsourcing effort, computational algorithm or big dataset from patient records to predict new uses of a drug or biologic. The key goal of this opportunity is to improve the data usability and efficiency of predicting new indications for existing therapeutics.


News Methods Funding Collaborations

Alzheimer's Association issues $7 million challenge to scientists to speed drug discovery

August 2nd 2016, Posted by: Drug Repurposing Portal

Alzheimer?s association in partnership with philanthropist Mikey Hoag of California in a fundraising initiative has announced a 7 million dollar investment in the clinical trials addressing brain inflammation in Alzheimer?s disease therapy. Four projects will receive 1 million dollars each to progress to the next stage and an additional 3 million dollar fund would be offered to the clinical trial with encouraging results. Three out of four studies are aimed at testing the potential of repurposing Leukine (approved against infections in chemotherapy patients), Sativex (for the treatment of spasticity in multiple sclerosis) and Senicapoc (proposed for sickle cell anemia) for slowing the progression of Alzheimer?s disease.


News Methods Funding Collaborations

Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

June 20th 2016, Posted by: Drug Repurposing Portal

Revive intends to use the net proceeds of the Rights Offering for a Phase 2 human proof of concept study for the treatment of Cystinuria assuming receipt of FDA acceptance and/or for non-clinical research studies, which would be used as part of the new drug application to the FDA to seek approval of Bucillamine for the treatment of Cystinuria and acute gout flares in the U.S., as well as working capital.


News Methods Funding Collaborations

Rare Diseases Drug Repurposing Funding Opportunities

May 30th 2016, Posted by: Drug Repurposing Portal

Muscular Dystrophy Canada, a non profit organization that strives to find a cure for neuromuscular disorders, added as a valued partner of our two rare diseases drug repurposing funding programs: E-Rare-3 Joint Transnational Call 2016 (JTC2016), and North American Re:Rare (NAR:R)


News Methods Funding Collaborations

Rare Diseases Drug Repurposing Funding Opportunities

May 11th 2016, Posted by: Drug Repurposing Portal

Canadian Institute of Health Research announces two different, E-Rare-3 rare diseases drug repurposing funding programs. Both opportunities are developed to encourage clinical research translational studies. The aim of the programme is to coordinate the research efforts of European countries in the field of rare diseases and implement the objectives of International Rare Disease Research Consortium (IRDiRC).


News Methods Funding Collaborations

Repurposing Social Impact Bonds for Medicine

April 8th 2016, Posted by: Drug Repurposing Portal

Cures Within Reach (CWR), a US based non-profit organization for drug repurposing efforts plans to address the funding gap repurposing initiatives. Bruce Booth (Founder, CWR) mentions that social impact bond (SIB), "pay for success" could be one of the ways to address this gap. CWR will prepare to pilot (evaluate 10 projects) the first SIB for the repurposing of generic drugs in England by partnering with FindACure, Numbers For Good, Costello Medical, and the UK's National Health Service.


News Methods Funding Collaborations

New Repurposing Research Funding Opportunity for Rare Diseases

January 11th 2016, Posted by: Drug Repurposing Portal

Cures Within Reach (www.cureswithinreach.org), a global non-profit focused on drug repurposing, has partnered with the Canadian Institutes of Health Research for a new funding initiative. Together they are calling for proposals for research into repurposing drugs specifically for rare diseases indications. This program is designed to encourage collaboration from clinical sites located both in Canada and the United States. A minimum of 10 projects will be selected for funding through this program.


News Methods Funding Collaborations

NCATS Matches Researchers with Pharmaceutical Industry Assets to Test Ideas for New Therapies

December 9th 2015, Posted by: Drug Repurposing Portal

NCATS recently awarded nearly $3 million to support four academic research groups that will test a selection of pharmaceutical industry assets for new therapeutic uses. The awarded projects are aimed at finding therapies for Type 2 diabetes, Glioblastoma, Acute myeloid leukemia, Chagas disease.


News Methods Funding Collaborations

NCATS Seeks Applications to Repurpose Existing Drugs

November 18th 2015, Posted by: Drug Repurposing Portal

NCATS is seeking applications for rigorous, pre-clinical research projects that are based on repurposing existing drugs or biologics. Through this new funding opportunity, NCATS anticipates committing $4.3 million in fiscal year 2016 to issue 10 to 15 awards in support of studies that establish the rationale for a clinical trial. Interested researchers should submit a letter of intent by Dec. 13, 2015. Applications are due Jan. 13, 2016.


News Methods Funding Collaborations

100 Drug Repurposing Projects in 100 Days

November 9th 2015, Posted by: Drug Repurposing Portal

CuresWithinReach (CWR), a non-profit organization encourages reserachers to post their ideas via their CureAccellerator platform within the next 100 days and aiming at initating 100 new repurposing projects. Repurposing reserach opportunities will also be spread across diease areas of interest and specific georaphical locations.


News Methods Funding Collaborations

Study Explores Nicotine Patch to Treat Memory Loss

November 5th 2015, Posted by: Drug Repurposing Portal

Vanderbilt University Medical Center has received a $9.4 million grant from the National Institute on Aging (NIA) to test the effectiveness of a transdermal nicotine patch in improving memory loss in older adults with mild cognitive impairment (MCI), a precursor to Alzheimer's disease.


News Methods Funding Collaborations

New treatment for Stroke Linked to Dementia

November 5th 2015, Posted by: Drug Repurposing Portal

A grant of GBP 850,000 was announced to researchers at the Universities of Edinburgh, Nottingham, and collaborators, to trial a new treatment for a type of stroke affecting around 35,000 people in the UK each year. Professor Wardlaw and colleagues will conduct three yearlong trial and patients will be treated with either cilostazol, isosorbide mononitrate or both and will monitor whether the drugs have an effect on the small vessels of the brain. If successful, the research could identify new ways of treating lacunar stroke and potentially prevent some forms of dementia. These two drugs are currently used to treat angina and peripheral vascular disease. This repurposed drug research could help prevent people from developing dementia following stroke.


News Methods Funding Collaborations

Houston Methodist and Weill Cornell Receive Nearly $3 Million to Identify Lung Cancer Therapy Targets

September 21st 2015, Posted by: Drug Repurposing Portal

Wong?s proprietary lab houses a computational model (P2GWAS) that uses powerful algorithms to analyze more than 10,000 known drugs, with the end goal of identifying drugs that can be repurposed for new uses. The NCI awarded the $2.8 million, five-year grant to Stephen T.C. Wong, Ph.D., P.E., Chair of the Department of Systems Medicine and Bioengineering at Houston Methodist Research Institute, and Vivek Mittal, Ph.D., director of the Neuberger Berman Foundation Lung Cancer Laboratory at Weill Cornell Medical College to study manipulation of tumor's microenvironment and figuring out how the tumor communicates with surrounding non-cancerous cells.


News Methods Funding Collaborations

Drug "Repurposing" specialist Acacia plans London IPO

September 14th 2015, Posted by: Drug Repurposing Portal

Acacia Pharma, a specialist in finding new uses for existing medicines or "repurposing" them, announced its plans to float in London, marking a further boost for British pharmaceutical and biotech fundraising, hoping to raise close to $230 million. Acacia Pharma famously repurposed amilsupride for the treatment of PONV and CINV using its proprietary delivery route and dosing that are appropriate for these indications, thus differentiating it from the original marketing product.


News Methods Funding Collaborations

Crowdfunding Gets Popular With Repurposing Drugs For Oncology

September 2nd 2015, Posted by: Drug Repurposing Portal

Prof. Sanjeev Krishna and team from St. George's University of London in partnership with BowelDiseaseUK opts for crowdfunding to conduct clinical trials for the use of 'Artesunate' (an existing safe anti-malarial drug) to treat bowel cancer. The bid opens on 22nd September and the team plans to utilize the money for clinical activities.


News Methods Funding Collaborations

NCI Funds Project On Repurposing Aspirin And A Diabetes Drug For Prostate Cancer

August 31st 2015, Posted by: Drug Repurposing Portal

National Cancer Institute has awarded an $852,705 Career Development Award to a population science researcher XiangLin Tan of Rutgers Cancer Institute, New Jersey for repurposing aspirin and metformin for prostate cancer prevention and control, especially in obese men. The anti-tumor efficacy of metformin and aspirin has been attributed to their insulin-lowering and anti-inflammatory properties. The study is aimed at understanding the mechanism by which metformin alone or in combination with aspirin will delay obesity-related prostate cancer progression by blocking the insulin/mTOR signaling & inflammation pathways.


News Methods Funding Collaborations

Orbus Gets $32.5m To Repurpose Hirsutism Drug For Brain Cancer

August 21st 2015, Posted by: Drug Repurposing Portal

Palo Alto-based Orbus Therapeutics received an impressive funding of $32.5 million to kick off Phase 3 trials of a FDA-approved eflornithine on a rare form of brain cancer. Eflornithine currently approved for African trypanosomiasis (sleeping sickness) and hirsutism can improve survival rates among patients with newly diagnosed or recurrent anaplastic astrocytoma; a rare and malignant form of brain cancer, by slowing down the rapid division of cancer cells. Funding for this round comes from Longitude Capital, H.I.G. BioVentures and Adam Street Partners. Notably, Dr. Ernest Mario, former deputy chairman of Glaxo Holdings and chairman and CEO of ALZA Corp., participated in the round as well.


News Methods Funding Collaborations

Ncats Funds To Test Ideas For New Therapies

July 24th 2015, Posted by: Drug Repurposing Portal

The NCATS recently awarded USD 3 Million to support 4 academic research groups that will work on Astrazeneca and Sanofi's compounds for new therapeutic uses as a part of their drug repurposing efforts. The new indications the groups are working on include Type 2 Diabetes (insulin resistance), Glioblastoma (EGFR activation), Acute Myeloid Leukemia (HDAC inhibition) and Chagas disease (Cathepsin S inhibitor).


News Methods Funding Collaborations

Creating New Economic Incentives For Repurposing Generic Drugs For Unsolved Diseases Using Social Finance

July 18th 2015, Posted by: Cures Within Reach

Bruce Bloom at Cures Within Reach, works on a unique 'Social Financing Model' for repurposing generic drugs. Since a lot of private investors are looking for returns on their investments (ROI), social impact bonds may be able to pay the investors who are funding such niche research at the same time provide effective, affordable medicines for unmet needs.


News Methods Funding Collaborations

Institute For Biomedical Sciences Researcher Gets $1.6 Million To Develop Anti-Inflammatory Drug

July 2nd 2015, Posted by: Drug Repurposing Portal

Dr. Jian-Dong Li, a professor and director of the Institute for Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 million federal grant to develop novel anti-inflammatory therapeutics against middle-ear infections. The grant from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health will support Li's drug development goals of identifying novel therapeutic targets and further developing non-antibiotic therapeutics to treat middle-ear infections by using drug repurposing.


News Methods Funding Collaborations

Clementia Bags $60m To Push A Repurposed Roche Drug Through Phase II

June 23rd 2015, Posted by: Drug Repurposing Portal

Canadian biotech Clementia Pharmaceuticals raised $60 million in mezzanine cash to help it fashion a once failed Roche ($RHHBY) drug into a promising treatment for a rare disease. Palovarotene, a retinoic acid receptor gamma agonist developed for the treatment for COPD but the project sidelined later. Noting the palovarotene has potential to block bone formation; Clementia picked it up with ambitions in fibrodysplasia ossificans progressiva (FOP), a rare and disabling disease characterized by tissue swelling and abnormal bone growth.


News Methods Funding Collaborations

Paradigm, A Drug Repurposing Company Aims At An IPO

June 15th 2015, Posted by: Drug Repurposing Portal

Paradigm Biopharmaceuticals is seeking to repurpose an existing drug, Pentosan Polysulphate Sodium (PPS) to treat common sports injury like bone bruising in the knee. Initially PPS has been used to treat blood clots, which acts as blood thinner. Currently there is not treatment for the bone bruising, hence paradigm strongly believes that PPS could have high success rate.


News Methods Funding Collaborations

HHS' Ventures Program Funds Collaborative Use Repurposing Engine (Cure)

June 12th 2015, Posted by: Drug Repurposing Portal

As a part of the HHS IDEA Lab to support federal employees for innovation, HHS Ventures funds a novel concept; Collaborative Use Repurposing Engine (CURE). CURE is online platform developed by FDA & NCATS to crowd-source medical information across the world to repurpose drugs for serious and neglected diseases.


News Methods Funding Collaborations

CPRIT Grants $6M to TAMHSC Repurposing Drug Program

June 2nd 2015, Posted by: Drug Repurposing Portal

The Texas A&M Health Science Center (TAMHSC) has been granted $6 million from the Cancer Research and Prevention Institute of Texas (CPRIT) to support the Combinatorial Drug Discovery Program from TAMHSC Institute for Biosciences and Technology (IBT). The research project is being developed based on a series of successful drugs which were approved by the US-FDA, with the purpose to develop novel therapies targeting different types of cancer.


News Methods Funding Collaborations

HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma

May 18th 2015, Posted by: Drug Repurposing Portal

In the scenario of drug repurposing, Hedge Path Pharmaceuticals to receive $2.5 Million in Funding From Mayne Pharma Hedge Path to shortly commence Phase II(b) skin cancer trial using Mayne Pharma's SUBA(TM)-Itraconazole, a drug previously used as the anti-fungal drug.


News Methods Funding Collaborations

Cures Within Reach Funds Research to Validation of a Companion Blood Test for Low-dose CT-based Screening Protocols for Lung Cancer

April 8th 2015, Posted by: Bruce Bloom

Dr. Jeff Borgia at Rush University Medical Center in Chicago, with financial support from Cures Within Reach and the Judy Hirsch Foundation is repurposing a blood test to help clinicians rule out non-malignant cases in other clinical circumstances. This research project would repurpose this diagnostic test to determine if it could reduce the need for biopsy-driven approaches and months of agonizing (and potentially disastrous) diagnostic delay in these high-risk patient scanning situations.


News Methods Funding Collaborations

University Spin-Out Gets Crowdfunding Investment To Develop A Cure For Parkinson'S Disease

March 9th 2015, Posted by: Drug Repurposing Portal

An Edinburgh University spin-out, Parkure; crowdsourced more than 75,000. The company aims to start screening drugs that have been classified as safe for human use on it's fruit-fly platform and outline promising lead candidates to cure Parkinson's Disease.


News Methods Funding Collaborations

Recursion Pharmaceuticals Wins $1.5M NIH Grant for Rare Disease Drug Discovery

February 25th 2015, Posted by: Drug Repurposing Portal

Recursion's receives NIH grant spread over 2 years and intends to build its drug screening platform for rare genetic diseases in multiple human cell types.


News Methods Funding Collaborations

Erectile Dysfunction Drug To Be Tested As Dementia Treatment

December 30th 2014, Posted by: Drug Repurposing Portal

Today, the Alzheimer s Drug Discovery Foundation (ADDF) and the Alzheimer s Society UK announced new funding to explore the possibility of using a commonly prescribed drug (Tadalafil) which treats erectile dysfunction as the next treatment for dementia. Nearly $500,000 will go to a team of scientists led by Dr. Atticus Hainsworth of St. George s University of London to research whether tadalafil, which works by dilating blood vessels, could help prevent vascular dementia by increasing blood flow to the brain.


News Methods Funding Collaborations

$562,500 Grant To Investigate Whether The Oral Contraceptive Drug Ormeloxifene Can Be Repurposed As A Prostate Cancer Treatment

December 17th 2014, Posted by: Drug Repurposing Portal

Subhash Chauhan, a professor in the Department of Pharmaceutical Sciences in the College of Pharmacy at UTHSC, has received a three-year grant worth $562,500 from the U.S. Department of Defense to research new therapies for advanced-stage prostate cancer. The grant is known as the DOD Idea Development Award. Chauhan will lead a team that will investigate whether the drug ormeloxifene can be repurposed as a prostate cancer treatment. Ormeloxifene is currently used as an oral contraceptive, but is believed to possess the capability to inhibit the pathways that signal metastasis and block estrogen and progesterone that trigger the abnormal cell growth. Because the drug is already in use and safe for human consumption, trials for cancer treatment could be done quickly.


News Methods Funding Collaborations

Charities Pledge To Jump-Start Drug Development For Brain Diseases

November 20th 2014, Posted by: Drug Repurposing Portal

Consortium seeks to uncover promising drugs in pharma libraries and conduct clinical trials.Drugs for brain diseases such as dementia, motor neurone disease and Parkinson's which have stalled in development could be revived thanks to up to 30 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Programme (Neuro-MAP), led by medical research charity MRC Technology and launched today (Tuesday 18 November 2014), will see charities and funding bodies identify promising drug projects no longer in development and help scientists to take them forward to the next stage.Neuro-MAP will ask pharmaceutical and biotechnology companies to propose projects to the consortium. The Neuro-MAP partner organisations will decide which projects to take on by evaluating patient needs, scientific excellence and commercial potential. Neuro-MAP projects will also support the repurposing of existing drugs and compounds for other conditions, such as testing hypertension drugs for vascular dementia.


News Methods Funding Collaborations

Seeking To End The 'Drug-Discovery Recession' For Mental Illness

November 19th 2014, Posted by: Drug Repurposing Portal

The first goal of the new Towson, Md-based institute formed by researchers at the Lieber Institute for Brain Development and doctors at Sheppard Pratt Health System is to reformulate an old Parkinson's drug to soothe aggression and aid memory in people suffering from such brain injuries.Officials expect the new institute to eventually translate discoveries of their own and others in genetics and brain functioning into better treatments for those suffering not just head injuries but schizophrenia, bipolar disorder, autism and other mental illnesses affecting millions of Americans.


News Methods Funding Collaborations

Transparency Life Sciences Awarded $14 Million NCATS SBIR Grant To Conduct Innovative Trial Of Lisinopril In Multiple Sclerosis

September 9th 2014, Posted by: Drug Repurposing Portal

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS). The $1.4 million grant, Repurposing a Generic ACE Inhibitor to Treat Multiple Sclerosis, was awarded by the National Center for Advancing Translational Sciences (NCATS) of the U.S. National Institutes of Health (NIH).


News Methods Funding Collaborations

UCSF Global Health Sciences Receives $6 Million For Three Neglected Diseases

May 26th 2014, Posted by: Drug Repurposing Portal

UC San Francisco, UC Berkeley and partner institutions received $6 Million from Bill & Melinda Gates Foundation and the Carlos Slim Health Institute to target Three Neglected Diseases: Chagas Disease, Dengue and Onchocerciasis.


News Methods Funding Collaborations

NCATS Announces Funding Opportunities To Repurpose Drug Candidates From Industry

May 23rd 2014, Posted by: Drug Repurposing Portal

NCATS Announces Funding Opportunities to Repurpose Drug Candidates from Industry on May 12th, 2014.


News Methods Funding Collaborations

NIH Awards Advaita $2M For Disease Subtyping, Drug Repurposing Technology Development

April 28th 2014, Posted by: Drug Repurposing Portal

National Institute Of General Medical Sciences of the National Institutes of Health granted $1.76M Phase II Small Business Investigational Research (SBIR) award to Advaita, a Bioinformatics company, to develop biological pathway analysis tools for personalized medicine and drug repositioning.


News Methods Funding Collaborations

Podcast: Drug That May Slow Parkinson S Progression Granted $23 Million From Nih For Phase Iii Testing

April 8th 2014, Posted by: Drug Repurposing Portal

Drug Isradipine a calcium channel blocker currently prescribed to treat high blood pressure is proceeding to Phase III testing for Parkinson's disease.


News Methods Funding Collaborations

Potential Parkinson'S Therapy Secures $23 Million For Testing From Nih After Foundation Funding

April 1st 2014, Posted by: Drug Repurposing Portal

Parkinson's Research (MJFF) have enabled researchers to secure a $23 million grant from the National Institutes of Health (NIH), continuing a repurposed drug approved for hypertension to Phase III testing for slowing Parkinson's progression. The trial investigating the compound isradipine will be the most advanced, current study into a disease-modifying therapy for Parkinson's, an unmet need.


News Methods Funding Collaborations

Cure Brain Cancer Foundation Is Providing Funding Opportunities For Finding Treatment Through Drug Repurposing For Brain Cancer

March 20th 2014, Posted by: Drug Repurposing Portal

Cure Brain cancer foundation is providing funding opportunities for finding treatment through drug repurposing for Brain cancer.


News Methods Funding Collaborations

Cures Within Reach Accepts Proposal For Rediscovery Research Projects (Repurposing)"

March 5th 2014, Posted by: Drug Repurposing Portal

Cures within reach accepts proposal for Rediscovery Research projects (Repurposing)".


News Methods Funding Collaborations

Nih Gambles On Recycled Drugs

February 25th 2014, Posted by: Drug Repurposing Portal

US$12.7 million was awarded by NIH last year (2013) towards drug repurposing.


News Methods Funding Collaborations

Alzheimer S & Dementia Weekly - Drug Repurposing Aims For New Alzheimer S Drugs, Faster

February 25th 2014, Posted by: Drug Repurposing Portal

Funding for Drug-repurposing research projects for "Alzheimer's disease" by the Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society (UK).


News Methods Funding Collaborations

Therapeutics For Rare And Neglected Diseases

February 25th 2014, Posted by: Drug Repurposing Portal

NCATS initiated TRND (THERAPEUTICS FOR RARE AND NEGLECTED DISEASES) program to facilitate the development of drugs for "Rare Diseases".


News Methods Funding Collaborations

Orphan Drug Startups Are On A Roll: Texas Biopharma Nabs $14M For Rare Autism Disorder

February 24th 2014, Posted by: Drug Repurposing Portal

Lumos Pharma gets $14 million funding from Sante Ventures and New Enterprise Associates for repurposing a small molecule drug (originally studied for use in solid tumors) for Autism disorder.


News Methods Funding Collaborations

Recursion Pharma Raises $13M in Funding

May 12th 0011, Posted by: Drug Repurposing Portal

Recursion Pharmaceuticals, a Salt Lake City, UT-based drug discovery company, raised $12.9m in Series A round of funding. The early focus includes drug repurposing and repositioning, a strategy which leverages existing safety and efficacy data to translate discoveries into the clinic more rapidly (and at lower cost) than building drugs from scratch. of Recursion. he company has already identified novel uses for known drugs, bioactive compounds, and shelved pharma assets in the space of rare genetic disease.


News Methods Funding Collaborations

Healx secures 1.5m pounds from Amadeus Capital to Combat Rare Diseases by 'Repurposing' Drugs

May 12th 0012, Posted by: Drug Repurposing Portal

Amadeus Capital Partners has made an early-stage investment in Healx, a British healthcare company that seeks new uses for existing drugs in the fight against rare diseases. Healx, founded and based in Cambridge, operates in the fast-growing drug 'repurposing' sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide.


News Methods Funding Collaborations
Load More